These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. Corbin JD; Francis SH J Androl; 2003; 24(6 Suppl):S38-41. PubMed ID: 14581493 [No Abstract] [Full Text] [Related]
65. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bunnage ME; Mathias JP; Wood A; Miller D; Street SD Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784 [TBL] [Abstract][Full Text] [Related]
66. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012 [TBL] [Abstract][Full Text] [Related]
67. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors. Yoo J; Thai KM; Kim DK; Lee JY; Park HJ Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682 [TBL] [Abstract][Full Text] [Related]
68. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction. Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243 [TBL] [Abstract][Full Text] [Related]
69. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II]. Baksheev BI; Kolomiets NM Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028 [TBL] [Abstract][Full Text] [Related]
70. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Qiu Y; Bhattacharjee S; Kraft P; Mathew John T; Haynes-Johnson D; Jiang W; Sui Z; Lundeen S Int J Impot Res; 2006; 18(5):477-83. PubMed ID: 16528290 [TBL] [Abstract][Full Text] [Related]
72. Pharmacology of erectile dysfunction in man. Cirino G; Fusco F; Imbimbo C; Mirone V Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277 [TBL] [Abstract][Full Text] [Related]
73. PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension. Deibert P; Bremer H; Roessle M; Kurz-Schmieg AK; Kreisel W Eur Respir J; 2007 Jan; 29(1):220-1. PubMed ID: 17197488 [No Abstract] [Full Text] [Related]
74. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]. Ghofrani HA; Grimminger F Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594 [TBL] [Abstract][Full Text] [Related]
75. Sex, the heart, and heart failure. Kiowski W; Brunner H; Schalcher C Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):256-8. PubMed ID: 16959762 [TBL] [Abstract][Full Text] [Related]
76. FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A). Lines TC; Ono M Phytomedicine; 2006 Mar; 13(4):236-9. PubMed ID: 16492525 [TBL] [Abstract][Full Text] [Related]
77. [After taking the table, immediate sex? New potency pill allows more time for love life]. MMW Fortschr Med; 2004 May; 146(19):64. PubMed ID: 15357491 [No Abstract] [Full Text] [Related]